Efficacy of alemtuzumab over 6 years in relapsing–remitting multiple sclerosis patients who relapsed between courses 1 and 2: Post hoc analysis of the CARE-MS studies

BACKGROUND: Alemtuzumab is administered as two annual courses for relapsing–remitting multiple sclerosis (MS). Patients may relapse before completing the two-course regimen. OBJECTIVE: The objective was to evaluate 6-year outcomes in patients who relapsed between alemtuzumab Courses 1 and 2 (early r...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Mult Scler
Autors principals: Van Wijmeersch, Bart, Singer, Barry A, Boster, Aaron, Broadley, Simon, Fernández, Óscar, Freedman, Mark S, Izquierdo, Guillermo, Lycke, Jan, Pozzilli, Carlo, Sharrack, Basil, Steingo, Brian, Wiendl, Heinz, Wray, Sibyl, Ziemssen, Tjalf, Chung, Luke, Margolin, David H, Thangavelu, Karthinathan, Vermersch, Patrick
Format: Artigo
Idioma:Inglês
Publicat: SAGE Publications 2019
Matèries:
Original Research Papers
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7604550/
https://ncbi.nlm.nih.gov/pubmed/31675266
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1352458519881759
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars